Class Ia antiarrhythmic drug cibenzoline: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy

Circulation

Volumn 96, Issue 5, 1997, Pages 1520-1524

  Hamada, Mareomi ^a   Shigematsu, Yuji ^a   Ikeda, Shuntaro ^a   Hara, Yuji ^a   Okayama, Hideki ^a   Kodama, Koji ^a   Ochi, Takaaki ^b   Hiwada, Kunio ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Takanoko Hospital   (Japan)

Author keywords

Antiarrhythmia agents; Cardiomyopathy; Contractility; Echocardiography; Hypertrophy

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CIBENZOLINE; DILTIAZEM; DISOPYRAMIDE; PROPRANOLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART LEFT VENTRICLE PRESSURE; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; M MODE ECHOCARDIOGRAPHY; MALE; ORAL DRUG ADMINISTRATION; POLYURIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030870039     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.5.1520     Document Type: Article

References (32)

1. ten Berg JM, Suttorp MJ, Knaepen PJ, Ernst SMPG, Vermeulen FEE, Jaarsma W. Hypertrophic obstructive cardiomyopathy: initial results and long-term follow-up after Morrow septal myectomy. Circulation. 1994;90:1781-1785.
2. Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation. 1995;92(suppl II):II-122-II-127.
3. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet. 1992; 339:1318-1323.
4. Fananapazir L, Cannon RO, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and β-adrenergic blocker therapy. Circulation. 1992;85:2149-2161.
5. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90: 2731-2742.
6. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med. 1982;307:997-999.
7. Sumimoto T, Hamada M, Ohtani T, Shigematsu Y, Fujiwara Y, Sekiya M, Hiwada K. Effect of disopyramide on systolic and early diastolic time intervals in patients with hypertrophic cardiomyopathy. J Clin Pharmacol. 1991;31:440-443.
8. Sumimoto T, Hamada M, Ohtani T, Suzuki M, Abe M, Matsuoka H, Fujiwara Y, Sekiya M, Hiwada K. Effect of disopyramide on left ventricular diastolic function in patients with hypertrophic cardiomyopathy: comparison with diltiazem. Cardiovasc Drugs Ther. 1992; 6:425-428.
9. Cazes M, Chassaing C, Martinet M, Cloarec A, Provost D, Boucher M, Duchene-Marullaz P. Comparison of anticholinergic effects of cibenzoline, disopyramide, and atropine. J Cardiovasc Pharmacol. 1990;15:308-316.
10. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J. 1980;44:672-673.
11. Sasson Z, Yock PG, Hatle LK, Alderman EL, Popp RL. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1988;11:752-756.
12. Khoo KC, Szuna AJ, Colburn WA, Aogaichi K, Morganroth J, Brazzell RK. Single-dose pharmacokinetics and dose proportionality of oral cibenzoline. J Clin Pharmacol. 1984;24:283-288.
13. Brazzell RK, Rees MMC, Khoo KC, Szuna AJ, Sandor D, Hannigan J. Age and cibenzoline disposition. Clin Pharmacol Ther. 1984;36:613-619.
14. Sahn DJ, DeMaria A, Kisslo J, Weyman A, The Committee on M-mode Standardization of The American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
15. Spirito P, Maron BJ. Significance of left ventricular outflow tract cross-sectional area in hypertrophic cardiomyopathy: a two-dimensional echocardiographic assessment. Circulation. 1983;67: 1100-1108.
16. Bryg RJ, Pearson AC, Williams GA, Labovitz AJ. Left ventricular systolic and diastolic flow abnormalities determined by Doppler echocardiography in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1987;59:925-931.
17. Hamada M, Ito T, Hiwada K, Kokubu T, Genda A, Takeda R. Characteristics of systolic time intervals in patients with pheochromocytoma. Jpn Circ J. 1991;55:417-426.
18. Weissler AM, Harris WS, Schoenfeld CD. Bedside technics for the evaluation of ventricular function in man. Am J Cardiol. 1969;23: 577-583.
19. Millar JS, Vaughan Williams EM. Pharmacological mapping of regional effects in the rabbit heart of some new antiarrhythmic drugs. Br J Pharmacol. 1983;79:701-709.
20. Millar JS, Vaughan Williams EM. Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. Br J Pharmacol. 1982;75:469-478.
21. Pollick C. Disopyramide in hypertrophic cardiomyopathy, II: noninvasive assessment after oral administration. Am J Cardiol. 1988; 62:1252-1255.
22. Pollick C, Giacomini KM, Blaschke TF, Nelson WL, Turner-Tamiyasu K, Briskin V, Popp RL. The cardiac effects of d- and 1-disopyramide in normal subjects: a noninvasive study. Circulation. 1982;66:447-453.
23. Pollick C, Rakowski H, Wigle ED. Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient. Circulation. 1984;69:43-49.
24. Lewis BS, Lewis N, Sapoznikov D, Gotsman MS. Isovolumic relaxation period in man. Am Heart J. 1980;100:490-499.
25. Hamada M, Matsuzaki K, Kazatani Y, Nishitani K, Daimon F, Ochi T, Ito T, Joh T, Kokubu T. Diagnostic significance of early diastolic time intervals in patients with hypertrophic cardiomyopathy and myocardial hypertrophy due to essential hypertension. Jpn Circ J. 1983;47:522-527.
26. Myreng Y, Smiseth OA. Assessment of left ventricular relaxation by Doppler echocardiography: comparison of isovolumic relaxation time and transmitral flow velocities with time constant of isovolumic relaxation. Circulation. 1990;81:260-266.
27. Hamada M, Suzuki M, Shigematsu Y, Abe M, Matsuoka H, Fujiwara Y, Sumimoto T, Sekiya M, Hiwada K. Does isovolumic relaxation time reflect the severity of left ventricular hypertrophy in patients with essential hypertension? Am J Noninvas Cardiol. 1992; 6:99-103.
28. Frank MJ, Abdulla AM, Watkins LO, Prisant L, Stefadouros MA. Long-term medical management of hypertrophic cardiomyopathy: usefulness of propranolol. Eur Heart J. 1983;4(suppl F):155-164.
29. Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, I: hemodynamic effects. Circulation. 1979;60:1201-1207.
30. Kaltenbach M, Hopf R, Kober G, Bussman WD, Keller M, Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979;42:35-42.
31. 2+ inward current by the class I antiarrhythmic agent, cibenzoline. Br J Pharmacol. 1986;87:705-711.
32. 2+ channel inhibitory effects of cibenzoline with verapamil on guinea-pig heart. Gen Pharmacol. 1991;22:87-91.